Increased antipsychotic sensitivity in elderly patients: Evidence and mechanisms

Hiroyuki Uchida, David C. Mamo, Benoit H. Mulsant, Bruce G. Pollock, Shitij Kapur

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Objective: The primary objective of this article is to review the literature regarding clinical effects, pharmacokinetics, and pharmacodynamics of antipsychotics in older people and to examine potential mechanisms underlying the age-related antipsychotic sensitivity. Data Sources: Data for this review were identified by searches of PubMed (1950-2007) and references from relevant articles and books. Search terms included antipsychotic, neuroleptic, elderly, aging, pharmacokinetics, pharmacodynamics, and dopamine, and only articles written in English or Japanese were consulted. Data Selection: Studies, reviews, and books pertaining to the clinical effects, pharmacokinetics, and pharmacodynamics with regard to the use of antipsychotics in older patients were selected. Data Synthesis: The prevailing practices and clinical guidelines suggest that elderly patients can obtain therapeutic benefits at a lower dose and experience adverse effects from antipsychotics more often than younger patients, although there are still few trials that have directly compared elderly patients with the young. The literature suggests an age-related increase in brain access of drugs and demonstrates a decrease with age in the principal components in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Conclusions: While clinicians conclusively hold that patients become more sensitive to antipsychotics as they become older, this proposition has only modest empirical support and warrants further investigation. Age-related functional decline in the dopaminergic system predicts lower antipsychotic doses for older patients. We propose a hierarchical series of testable hypotheses to address the relative contribution of age-related pharmacokinetic and pharmacodynamic changes to antipsychotic drug sensitivity.

Original languageEnglish
Pages (from-to)397-405
Number of pages9
JournalJournal of Clinical Psychiatry
Volume70
Issue number3
DOIs
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

Antipsychotic Agents
Pharmacokinetics
Dopamine
Information Storage and Retrieval
Dopamine Receptors
Practice Guidelines
PubMed
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Increased antipsychotic sensitivity in elderly patients : Evidence and mechanisms. / Uchida, Hiroyuki; Mamo, David C.; Mulsant, Benoit H.; Pollock, Bruce G.; Kapur, Shitij.

In: Journal of Clinical Psychiatry, Vol. 70, No. 3, 03.2009, p. 397-405.

Research output: Contribution to journalArticle

Uchida, Hiroyuki ; Mamo, David C. ; Mulsant, Benoit H. ; Pollock, Bruce G. ; Kapur, Shitij. / Increased antipsychotic sensitivity in elderly patients : Evidence and mechanisms. In: Journal of Clinical Psychiatry. 2009 ; Vol. 70, No. 3. pp. 397-405.
@article{9f6ba8fd5e374dd094d665655ca0dbf3,
title = "Increased antipsychotic sensitivity in elderly patients: Evidence and mechanisms",
abstract = "Objective: The primary objective of this article is to review the literature regarding clinical effects, pharmacokinetics, and pharmacodynamics of antipsychotics in older people and to examine potential mechanisms underlying the age-related antipsychotic sensitivity. Data Sources: Data for this review were identified by searches of PubMed (1950-2007) and references from relevant articles and books. Search terms included antipsychotic, neuroleptic, elderly, aging, pharmacokinetics, pharmacodynamics, and dopamine, and only articles written in English or Japanese were consulted. Data Selection: Studies, reviews, and books pertaining to the clinical effects, pharmacokinetics, and pharmacodynamics with regard to the use of antipsychotics in older patients were selected. Data Synthesis: The prevailing practices and clinical guidelines suggest that elderly patients can obtain therapeutic benefits at a lower dose and experience adverse effects from antipsychotics more often than younger patients, although there are still few trials that have directly compared elderly patients with the young. The literature suggests an age-related increase in brain access of drugs and demonstrates a decrease with age in the principal components in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Conclusions: While clinicians conclusively hold that patients become more sensitive to antipsychotics as they become older, this proposition has only modest empirical support and warrants further investigation. Age-related functional decline in the dopaminergic system predicts lower antipsychotic doses for older patients. We propose a hierarchical series of testable hypotheses to address the relative contribution of age-related pharmacokinetic and pharmacodynamic changes to antipsychotic drug sensitivity.",
author = "Hiroyuki Uchida and Mamo, {David C.} and Mulsant, {Benoit H.} and Pollock, {Bruce G.} and Shitij Kapur",
year = "2009",
month = "3",
doi = "10.4088/JCP.08r04171",
language = "English",
volume = "70",
pages = "397--405",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - Increased antipsychotic sensitivity in elderly patients

T2 - Evidence and mechanisms

AU - Uchida, Hiroyuki

AU - Mamo, David C.

AU - Mulsant, Benoit H.

AU - Pollock, Bruce G.

AU - Kapur, Shitij

PY - 2009/3

Y1 - 2009/3

N2 - Objective: The primary objective of this article is to review the literature regarding clinical effects, pharmacokinetics, and pharmacodynamics of antipsychotics in older people and to examine potential mechanisms underlying the age-related antipsychotic sensitivity. Data Sources: Data for this review were identified by searches of PubMed (1950-2007) and references from relevant articles and books. Search terms included antipsychotic, neuroleptic, elderly, aging, pharmacokinetics, pharmacodynamics, and dopamine, and only articles written in English or Japanese were consulted. Data Selection: Studies, reviews, and books pertaining to the clinical effects, pharmacokinetics, and pharmacodynamics with regard to the use of antipsychotics in older patients were selected. Data Synthesis: The prevailing practices and clinical guidelines suggest that elderly patients can obtain therapeutic benefits at a lower dose and experience adverse effects from antipsychotics more often than younger patients, although there are still few trials that have directly compared elderly patients with the young. The literature suggests an age-related increase in brain access of drugs and demonstrates a decrease with age in the principal components in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Conclusions: While clinicians conclusively hold that patients become more sensitive to antipsychotics as they become older, this proposition has only modest empirical support and warrants further investigation. Age-related functional decline in the dopaminergic system predicts lower antipsychotic doses for older patients. We propose a hierarchical series of testable hypotheses to address the relative contribution of age-related pharmacokinetic and pharmacodynamic changes to antipsychotic drug sensitivity.

AB - Objective: The primary objective of this article is to review the literature regarding clinical effects, pharmacokinetics, and pharmacodynamics of antipsychotics in older people and to examine potential mechanisms underlying the age-related antipsychotic sensitivity. Data Sources: Data for this review were identified by searches of PubMed (1950-2007) and references from relevant articles and books. Search terms included antipsychotic, neuroleptic, elderly, aging, pharmacokinetics, pharmacodynamics, and dopamine, and only articles written in English or Japanese were consulted. Data Selection: Studies, reviews, and books pertaining to the clinical effects, pharmacokinetics, and pharmacodynamics with regard to the use of antipsychotics in older patients were selected. Data Synthesis: The prevailing practices and clinical guidelines suggest that elderly patients can obtain therapeutic benefits at a lower dose and experience adverse effects from antipsychotics more often than younger patients, although there are still few trials that have directly compared elderly patients with the young. The literature suggests an age-related increase in brain access of drugs and demonstrates a decrease with age in the principal components in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Conclusions: While clinicians conclusively hold that patients become more sensitive to antipsychotics as they become older, this proposition has only modest empirical support and warrants further investigation. Age-related functional decline in the dopaminergic system predicts lower antipsychotic doses for older patients. We propose a hierarchical series of testable hypotheses to address the relative contribution of age-related pharmacokinetic and pharmacodynamic changes to antipsychotic drug sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=64149112639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64149112639&partnerID=8YFLogxK

U2 - 10.4088/JCP.08r04171

DO - 10.4088/JCP.08r04171

M3 - Article

C2 - 19192476

AN - SCOPUS:64149112639

VL - 70

SP - 397

EP - 405

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3

ER -